Therapeutic potential of fosmanogepix (APX001) for intra-abdominal candidiasis: From lesion penetration to efficacy in a mouse model

Annie Lee, Ning Wang, Claire L. Carter, Matthew Zimmerman, Véronique Dartois, Karen Joy Shaw, David S. Perlin, Yanan Zhao

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Intra-abdominal candidiasis (IAC) is one of the most common yet under-appreciated forms of invasive candidiasis. IAC is difficult to treat, and therapeutic failure and drug-resistant breakthrough infections are common in some institutions despite the use of echinocandins as first-line agents. Fosmanogepix (FMGX, formerly APX001) is a first-in-class antifungal prodrug that can be administered both intravenously and orally. FMGX is currently in phase 2 clinical development for the treatment of life-threatening invasive fungal infections. To explore the pharmacological properties and therapeutic potential of FMGX for IAC, we evaluated both drug penetration and efficacy of the active moiety manogepix (MGX, formerly APX001A) in liver tissues in a clinically relevant IAC mouse model infected with Candida albicans. Matrix-assisted laser desorption ionization–mass spectrometry imaging (MALDI-MSI) and laser capture microdissection (LCM)-directed absolute drug quantitation were employed to evaluate drug penetration into liver abscess lesions both spatially and quantitatively. The partitioning of MGX into lesions occurred slowly after a single dose; however, robust accumulation in the lesion was achieved after 3days of repeated dosing. Associated with this drug penetration pattern, reduction in fungal burden and clearance in the liver were observed in mice receiving the multiday FMGX regimen. In comparison, administration of micafungin resulted in marginal reduction in fungal burden at the end of 4days of treatment. These results suggest that FMGX is a promising candidate for the treatment of IAC.

Original languageEnglish (US)
Article numbere02476-20
JournalAntimicrobial agents and chemotherapy
Issue number4
StatePublished - Apr 2021
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


  • APX001
  • APX001A
  • Drug penetration
  • FMGX
  • Fosmanogepix
  • Fosmanogepix (FMGX)
  • Intra-abdominal candidiasis
  • Laser capture microdissection (LCM)
  • Lesion
  • MGX
  • Manogepix
  • Manogepix (MGX)
  • Matrix-assisted desorption ionization–mass spectrometry imaging (MALDI-MSI)


Dive into the research topics of 'Therapeutic potential of fosmanogepix (APX001) for intra-abdominal candidiasis: From lesion penetration to efficacy in a mouse model'. Together they form a unique fingerprint.

Cite this